A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis

Do Seon Song, Myeong Jun Song, Si Hyun Bae, Woo Jin Chung, Jae Young Jang, Young Seok Kim, Sae Hwan Lee, Jun Yong Park, Hyung Joon Yim, Sung Bum Cho, Soo Young Park, Jin Mo Yang

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Background: The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT). Methods: A total of 110 patients were observed between February 2008 and May 2013 in seven Korean centers. Fifty patients were treated with HAIC, and 60 patients were treated with sorafenib. Results: The disease control rate in the HAIC was significantly higher than that in the sorafenib group (p < 0.001), although there was no significant difference in the objective response rate (p = 0.214). The median overall survival (OS) was significantly longer in the HAIC group than in the sorafenib group (7.1 vs. 5.5 months, p = 0.011). The median time to-progression (TTP) was also significantly longer in the HAIC group than in the sorafenib group (3.3 vs. 2.1 months, p = 0.034). In the multivariate analysis, tumor diameter (≥ 10 cm) and the absence of combined loco-regional treatment were significant prognostic factors influencing OS (p = 0.002 and p = 0.010, respectively) and TTP (p = 0.017 and p = 0.006, respectively). The treatment modality tended to be a significant prognostic factor for survival (p = 0.052), but not for tumor progression (p = 0.121). Conclusions: HAIC is comparable with sorafenib in terms of OS and TTP in advanced HCC patients with PVTT. HAIC shows more favorable treatment responses compared with sorafenib. Therefore, HAIC might be an alternative treatment modality to sorafenib in advanced HCC patients with PVTT.

Original languageEnglish
Pages (from-to)445-454
Number of pages10
JournalJournal of Gastroenterology
Volume50
Issue number4
DOIs
Publication statusPublished - 2015 Apr 1

Fingerprint

Portal Vein
Hepatocellular Carcinoma
Thrombosis
Drug Therapy
Liver
Neoplasms
Survival
sorafenib
Therapeutics
Multivariate Analysis

Keywords

  • Hepatic arterial infusion chemotherapy
  • Hepatocellular carcinoma
  • Portal vein tumor thrombosis
  • Sorafenib

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. / Song, Do Seon; Song, Myeong Jun; Bae, Si Hyun; Chung, Woo Jin; Jang, Jae Young; Kim, Young Seok; Lee, Sae Hwan; Park, Jun Yong; Yim, Hyung Joon; Cho, Sung Bum; Park, Soo Young; Yang, Jin Mo.

In: Journal of Gastroenterology, Vol. 50, No. 4, 01.04.2015, p. 445-454.

Research output: Contribution to journalArticle

Song, Do Seon ; Song, Myeong Jun ; Bae, Si Hyun ; Chung, Woo Jin ; Jang, Jae Young ; Kim, Young Seok ; Lee, Sae Hwan ; Park, Jun Yong ; Yim, Hyung Joon ; Cho, Sung Bum ; Park, Soo Young ; Yang, Jin Mo. / A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. In: Journal of Gastroenterology. 2015 ; Vol. 50, No. 4. pp. 445-454.
@article{5864d4fc725441eb916bde5384715a5a,
title = "A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis",
abstract = "Background: The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT). Methods: A total of 110 patients were observed between February 2008 and May 2013 in seven Korean centers. Fifty patients were treated with HAIC, and 60 patients were treated with sorafenib. Results: The disease control rate in the HAIC was significantly higher than that in the sorafenib group (p < 0.001), although there was no significant difference in the objective response rate (p = 0.214). The median overall survival (OS) was significantly longer in the HAIC group than in the sorafenib group (7.1 vs. 5.5 months, p = 0.011). The median time to-progression (TTP) was also significantly longer in the HAIC group than in the sorafenib group (3.3 vs. 2.1 months, p = 0.034). In the multivariate analysis, tumor diameter (≥ 10 cm) and the absence of combined loco-regional treatment were significant prognostic factors influencing OS (p = 0.002 and p = 0.010, respectively) and TTP (p = 0.017 and p = 0.006, respectively). The treatment modality tended to be a significant prognostic factor for survival (p = 0.052), but not for tumor progression (p = 0.121). Conclusions: HAIC is comparable with sorafenib in terms of OS and TTP in advanced HCC patients with PVTT. HAIC shows more favorable treatment responses compared with sorafenib. Therefore, HAIC might be an alternative treatment modality to sorafenib in advanced HCC patients with PVTT.",
keywords = "Hepatic arterial infusion chemotherapy, Hepatocellular carcinoma, Portal vein tumor thrombosis, Sorafenib",
author = "Song, {Do Seon} and Song, {Myeong Jun} and Bae, {Si Hyun} and Chung, {Woo Jin} and Jang, {Jae Young} and Kim, {Young Seok} and Lee, {Sae Hwan} and Park, {Jun Yong} and Yim, {Hyung Joon} and Cho, {Sung Bum} and Park, {Soo Young} and Yang, {Jin Mo}",
year = "2015",
month = "4",
day = "1",
doi = "10.1007/s00535-014-0978-3",
language = "English",
volume = "50",
pages = "445--454",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis

AU - Song, Do Seon

AU - Song, Myeong Jun

AU - Bae, Si Hyun

AU - Chung, Woo Jin

AU - Jang, Jae Young

AU - Kim, Young Seok

AU - Lee, Sae Hwan

AU - Park, Jun Yong

AU - Yim, Hyung Joon

AU - Cho, Sung Bum

AU - Park, Soo Young

AU - Yang, Jin Mo

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background: The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT). Methods: A total of 110 patients were observed between February 2008 and May 2013 in seven Korean centers. Fifty patients were treated with HAIC, and 60 patients were treated with sorafenib. Results: The disease control rate in the HAIC was significantly higher than that in the sorafenib group (p < 0.001), although there was no significant difference in the objective response rate (p = 0.214). The median overall survival (OS) was significantly longer in the HAIC group than in the sorafenib group (7.1 vs. 5.5 months, p = 0.011). The median time to-progression (TTP) was also significantly longer in the HAIC group than in the sorafenib group (3.3 vs. 2.1 months, p = 0.034). In the multivariate analysis, tumor diameter (≥ 10 cm) and the absence of combined loco-regional treatment were significant prognostic factors influencing OS (p = 0.002 and p = 0.010, respectively) and TTP (p = 0.017 and p = 0.006, respectively). The treatment modality tended to be a significant prognostic factor for survival (p = 0.052), but not for tumor progression (p = 0.121). Conclusions: HAIC is comparable with sorafenib in terms of OS and TTP in advanced HCC patients with PVTT. HAIC shows more favorable treatment responses compared with sorafenib. Therefore, HAIC might be an alternative treatment modality to sorafenib in advanced HCC patients with PVTT.

AB - Background: The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT). Methods: A total of 110 patients were observed between February 2008 and May 2013 in seven Korean centers. Fifty patients were treated with HAIC, and 60 patients were treated with sorafenib. Results: The disease control rate in the HAIC was significantly higher than that in the sorafenib group (p < 0.001), although there was no significant difference in the objective response rate (p = 0.214). The median overall survival (OS) was significantly longer in the HAIC group than in the sorafenib group (7.1 vs. 5.5 months, p = 0.011). The median time to-progression (TTP) was also significantly longer in the HAIC group than in the sorafenib group (3.3 vs. 2.1 months, p = 0.034). In the multivariate analysis, tumor diameter (≥ 10 cm) and the absence of combined loco-regional treatment were significant prognostic factors influencing OS (p = 0.002 and p = 0.010, respectively) and TTP (p = 0.017 and p = 0.006, respectively). The treatment modality tended to be a significant prognostic factor for survival (p = 0.052), but not for tumor progression (p = 0.121). Conclusions: HAIC is comparable with sorafenib in terms of OS and TTP in advanced HCC patients with PVTT. HAIC shows more favorable treatment responses compared with sorafenib. Therefore, HAIC might be an alternative treatment modality to sorafenib in advanced HCC patients with PVTT.

KW - Hepatic arterial infusion chemotherapy

KW - Hepatocellular carcinoma

KW - Portal vein tumor thrombosis

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84939885737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939885737&partnerID=8YFLogxK

U2 - 10.1007/s00535-014-0978-3

DO - 10.1007/s00535-014-0978-3

M3 - Article

C2 - 25027973

AN - SCOPUS:84939885737

VL - 50

SP - 445

EP - 454

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 4

ER -